Tag: basophil activation test

Come Visit BUHLMANN at AMLI 2017- Booth #13

     AMLI 2017 BUHLMANN Diagnostics Corp  Booth: #13 August 13 - 16, 2017 Renaissance Stapleton Hotel | Denver, C0 LEARN MORE Click & Contact our AMLI 2017BUHLMANN Team Connect with our team ahead of time, learn more about the BÜHLMANN's Products and Solutions or schedule a meeting! Jennifer Stuart, Technical Sales Specialist JENNIFER STUART Technical Sales Specialist jls@buhlmannlabs.com
Continue Reading

Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease

Flow CAST® – Kinase Inhibtion Assay Citation: Matthews, D.J. et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 2012 New York Academy of Sciences Meeting Poster.  "Importantly, PWT143 inhibits basophil activation (as measured by surface CD63 expression in a whole blood assay) with subnanomolar potency in response to anti-IgE stimulation
Continue Reading

TGR-1202 Suppresses Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Cells via Selective Inhibition of PI3Kδ Kinase

Flow CAST® – Kinase Inhibtion Assay Citation: VakkalankaS. et al. TGR-1202 suppresses acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells via selective inhibition of PI3Kδ kinase. 2012 ASH Meeting Poster. "TGR-1202 demonstrated significant potency against PI3Kδ (22.2 nM) with several fold selectivity over the α (>10000), β (>50), and γ (>48) isoforms. Additionally, the
Continue Reading

Brutontyrosine Kinase Inhibitor Ibrutinib(PCI-32765) has Significant Activity in Patients with Relapsed/Refractory B-cell Malignancies

Flow CAST® – Kinase Inhibtion Assay Citation: Advani, R.H. et al. Brutontyrosine kinase inhibitor ibrutinib(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J ClinOncol. 2013 Jan 1; 31(1): 88-94. PMID: 23045577 "A decrease in anti–IgE-stimulated basophil degranulation was observed, consistent with the role of BTK downstream of the high-affinity IgE receptor."
Continue Reading

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

Flow CAST® – Kinase Inhibtion Assay Citation: Winkler, DG et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. PMID: 24211136. "These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting
Continue Reading

BUHLMANN announces new Microsite for Kinase Inhibition Assay

BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYK pathways are a large focus for pharmaceutical
Continue Reading

BÜHLMANN CAST® Drug Allergens: New Products

We are pleased to announce 2 new BÜHLMANN CAST® Drug Allergens: Tramadol and Metoprolol In order to meet the needs of your Cellular Allergy testing, we are offering an extended allergen portfolio by enriching this product line with new Analgesic and Beta Blocker allergens. Tramadol and Metroprolol are for Research Use Only.  Not for use in diagnostic procedures.
Continue Reading

Flow CAST® eBook- Kinase Inhibition Assay for BTK, SYK, and PI3K Activity

Flow CAST® eBook Testing Potency and Efficacy of Inhibitors of PI3K, PI3K, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,